{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:04:04Z","timestamp":1771542244713,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.parkreldis.2023.105356","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T14:27:28Z","timestamp":1678026448000},"page":"105356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1148-084X","authenticated-orcid":false,"given":"Beatriz H.","family":"Thames","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2023.105356_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with Parkinson's disease (1991-2010)","volume":"12","author":"Stang","year":"2022","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2023.105356_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2023.105356_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson's disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2023.105356_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2008.04.026","article-title":"Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs","volume":"272","author":"Sitburana","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105356_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"issue":"9896","key":"10.1016\/j.parkreldis.2023.105356_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.parkreldis.2023.105356_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40266-019-00655-y","article-title":"Pimavanserin for psychosis in Parkinson's disease-related Disorders: a retrospective chart review","volume":"36","author":"Sellers","year":"2019","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105356_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1176\/appi.neuropsych.18080180","article-title":"Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism","volume":"31","author":"Chen","year":"2019","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105356_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mdc3.12266","article-title":"Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action","volume":"3","author":"Yaw","year":"2016","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105356_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:27:13Z","timestamp":1761179233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802023000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":10,"alternative-id":["S1353802023000792"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105356","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105356"}}